Similar results were obtained when tumours were treated with digoxin rather than digitoxin (Supplementary Fig. 3a,b) or when the MAPK pathway was inhibited with BRAF inhibitor (vemurafenib) rather than MEK inhibitor (Supplementary Fig. 3c,d). This evidence concerns the gene BRAF and neoplasm.